Compound ID | 1794
Synonym(s): BV300
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Enterobacteriaceae and Acinetobacter, binding to the protein 50S ribosomal subunit |
| Description: | Synthetic compound. Acquired from Melinta Therapeutics |
| Institute where first reported: | Bioversys AG (Melinta Therapeutics formerly Rib-X Pharmaceutical) |
| Year first mentioned: | 2018 |
| Highest development stage: | Preclinical |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | RX-04A |
| Citations: |
|